5,657 reports of this reaction
2.5% of all VEDOLIZUMAB reports
#8 most reported adverse reaction
HAEMATOCHEZIA is the #8 most commonly reported adverse reaction for VEDOLIZUMAB, manufactured by Takeda Pharmaceuticals America, Inc.. There are 5,657 FDA adverse event reports linking VEDOLIZUMAB to HAEMATOCHEZIA. This represents approximately 2.5% of all 224,197 adverse event reports for this drug.
VEDOLIZUMAB has an overall safety score of 88 out of 100. Patients taking VEDOLIZUMAB who experience haematochezia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMATOCHEZIA is a less commonly reported adverse event for VEDOLIZUMAB, but still significant enough to appear in the safety profile.
In addition to haematochezia, the following adverse reactions have been reported for VEDOLIZUMAB:
The following drugs have also been linked to haematochezia in FDA adverse event reports:
HAEMATOCHEZIA has been reported as an adverse event in 5,657 FDA reports for VEDOLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMATOCHEZIA accounts for approximately 2.5% of all adverse event reports for VEDOLIZUMAB, making it a notable side effect.
If you experience haematochezia while taking VEDOLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.